EA201001569A1 - Инкапсуляция биологически активных агентов - Google Patents

Инкапсуляция биологически активных агентов

Info

Publication number
EA201001569A1
EA201001569A1 EA201001569A EA201001569A EA201001569A1 EA 201001569 A1 EA201001569 A1 EA 201001569A1 EA 201001569 A EA201001569 A EA 201001569A EA 201001569 A EA201001569 A EA 201001569A EA 201001569 A1 EA201001569 A1 EA 201001569A1
Authority
EA
Eurasian Patent Office
Prior art keywords
biologically active
active agents
incapsulation
agents
compositions
Prior art date
Application number
EA201001569A
Other languages
English (en)
Inventor
Айрин Папаниколаоу
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of EA201001569A1 publication Critical patent/EA201001569A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Согласно настоящему изобретению предложены способы инкапсуляции биологически активных агентов, таких как белки, в носители в форме частиц, такие как наночастицы, с использованием агентов для образования пар гидрофобных ионов (HIP-агентов). Также предложены композиции, содержащие носители в форме частиц, получаемые такими способами, и применения таких композиций в лечении.
EA201001569A 2008-05-06 2009-05-05 Инкапсуляция биологически активных агентов EA201001569A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5077508P 2008-05-06 2008-05-06
US7417108P 2008-06-20 2008-06-20
PCT/EP2009/055438 WO2009135855A2 (en) 2008-05-06 2009-05-05 Encapsulation of biologically active agents

Publications (1)

Publication Number Publication Date
EA201001569A1 true EA201001569A1 (ru) 2011-10-31

Family

ID=43125562

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001569A EA201001569A1 (ru) 2008-05-06 2009-05-05 Инкапсуляция биологически активных агентов

Country Status (12)

Country Link
US (1) US20110059142A1 (ru)
EP (1) EP2273986A2 (ru)
JP (1) JP2011519894A (ru)
CN (1) CN102215830A (ru)
AU (1) AU2009245786A1 (ru)
BR (1) BRPI0912230A2 (ru)
CA (1) CA2721350A1 (ru)
EA (1) EA201001569A1 (ru)
IL (1) IL208655A0 (ru)
MX (1) MX2010012136A (ru)
WO (1) WO2009135855A2 (ru)
ZA (1) ZA201007436B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520802A (ja) * 2008-05-06 2011-07-21 グラクソ グループ リミテッド 生物活性薬の封入
AU2014318566A1 (en) * 2013-09-12 2016-04-07 Thomas Jefferson University Novel delivery compositions and methods of using same
CN106163503B (zh) * 2014-03-14 2021-02-26 辉瑞大药厂 包含治疗剂的治疗性纳米颗粒及其制造及使用方法
EP3148516A1 (en) * 2014-05-30 2017-04-05 AbbVie Deutschland GmbH & Co. KG Nanoencapsulation of antigen-binding molecules
AU2015284236B2 (en) 2014-06-30 2018-03-08 Tva (Abc), Llc Targeted conjugates and particles and formulations thereof
CN104771362B (zh) * 2014-09-03 2018-01-02 沈阳药科大学 一种克拉霉素离子对脂质微球注射液及其制备方法
JP7057278B2 (ja) 2015-10-28 2022-04-19 ターベダ セラピューティクス インコーポレイテッド Ｓｓｔｒ標的化コンジュゲート及び粒子並びにその製剤
WO2017085212A2 (en) * 2015-11-20 2017-05-26 AbbVie Deutschland GmbH & Co. KG Surface-modified nanospheres encapsulating antigen-binding molecules
US11833486B2 (en) * 2015-11-29 2023-12-05 Berney PENG Functionalized nanoparticles having encapsulated guest cargo and methods for making the same
US11484505B2 (en) 2016-10-13 2022-11-01 Thomas Jefferson University Delivery compositions, and methods of making and using same
CN109260174B (zh) * 2018-09-04 2021-10-15 中山大学 一种治疗性蛋白纳米颗粒的高通量制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2649321A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
GB9300875D0 (en) * 1993-01-18 1993-03-10 Ucb Sa Nanocapsule containing pharmaceutical compositions
WO1995007072A2 (de) * 1993-09-09 1995-03-16 Schering Aktiengesellschaft Wirkstoffe und gas enthaltende mikropartikel
US20030152636A1 (en) * 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
EP1417236A4 (en) * 2001-07-10 2010-03-17 Corixa Corp COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ENCAPSULATED PROTEINS AND ADJUVANTS IN MICROSPHERES
ES2741576T3 (es) * 2003-07-23 2020-02-11 Evonik Corp Composiciones de liberación controlada

Also Published As

Publication number Publication date
WO2009135855A2 (en) 2009-11-12
US20110059142A1 (en) 2011-03-10
WO2009135855A3 (en) 2011-01-27
EP2273986A2 (en) 2011-01-19
CA2721350A1 (en) 2009-11-12
MX2010012136A (es) 2010-12-17
BRPI0912230A2 (pt) 2017-08-22
CN102215830A (zh) 2011-10-12
ZA201007436B (en) 2012-03-28
AU2009245786A1 (en) 2009-11-12
JP2011519894A (ja) 2011-07-14
IL208655A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
EA201001569A1 (ru) Инкапсуляция биологически активных агентов
EA201200951A1 (ru) Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
EA201391030A1 (ru) Композиции моноциклина для местного применения и способы их применения
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA201190170A1 (ru) Композиции полимера мирцена
EA201170659A1 (ru) Антитела к рецептору ii tgf-вета
EA200970747A1 (ru) Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком
WO2009135853A3 (en) Encapsulation of biologically active agents
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
EA202091230A3 (ru) Антагонисты активин-actrii и их применения для повышения уровней эритроцитов
EA201190295A1 (ru) Композиции для дермальной доставки, содержащие комплексы активного агента с частицами фосфата кальция, и способы их применения
TR201900670T4 (tr) İnhalasyon için yöntem ve formülasyon.
EA201001699A1 (ru) Сложные эфиры и тиоэфиры тиазол-4-карбоновой кислоты в качестве средств защиты растений
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX2011010673A (es) Formulaciones de nanoparticulas y usos de las mismas.
CO6351786A2 (es) Inkibidores de la cinasa map p38
MX2012002927A (es) Anticuerpos humanos de alta afinidad con el receptor activado por proteasa humana-2.
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201400903A1 (ru) Композиции глины
WO2009135190A3 (en) Therapeutic calcium phosphate particles and methods of making and using same
EA201001283A1 (ru) Комбинация витамина d и 25-гидроксивитамина d3
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
ATE555108T1 (de) Polyamide zur behandlung des menschlichen papilloma-virus
EA201391555A1 (ru) Составы суспензионного типа для местного применения, содержащие циклический депсипептид